Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Phase 4
Completed
- Conditions
- Chronic Stable Heart Failure
- Registration Number
- NCT00663195
- Lead Sponsor
- Tottori University Hospital
- Brief Summary
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.
- Detailed Description
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with chronic heart failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF animal models. Therefore, the purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels in patients with chronic heart failure.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
- chronic stable heart failure
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method MMP levels 16 weeks
- Secondary Outcome Measures
Name Time Method